Impact of food and herbal medication on calcineurin inhibitor dose in renal transplant patients: A cross-sectional study

Journal of Medicinal Food

Volumn 14, Issue 7-8, 2011, Pages 756-760

  Nowack, Rainer ^a   Ballé, Christoph ^b   Birnkammer, Franz ^a   Koch, Wolfgang ^c   Sessler, Roland ^a   Birck, Rainer ^d  

^a Center for Nephrology and Dialysis   (Germany)

^b Center for Nephrology and Dialysis   (Germany)

^c Center for Nephrology and Dialysis   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

calcineurin inhibitor; cyclosporin A; herbal interaction; herbal teas; renal transplant patients; St. John's wort; tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHAMOMILE; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POTASSIUM; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CACAO; CHICORY; CHRONIC ALLOGRAFT NEPHROPATHY; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; GRAFT RECIPIENT; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPOVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERVIEW; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SPICE; TEA; URINE VOLUME;

ADULT; AGED; CALCINEURIN; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; EATING; ENZYME INHIBITORS; FEMALE; FOOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLANT PREPARATIONS; PLANTS, MEDICINAL; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; YOUNG ADULT;

CICHORIUM INTYBUS;

EID: 79960458306     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2010.0163     Document Type: Article

References (15)

1. Nowack R, Ballé C, Birnkammer F, Koch W, Sessler R, Birck R: Complementary and alternative medication consumed by renal patients in southern Germany. J Ren Nutr 2009;19:211-219.
2. Hess S, De Geest S, Halter K, Dickenmann M, Denhaerynck K: Prevalence and correlates of selected alternative and complementary medicine in adult renal transplant patients. Clin Transplant 2009;23:56-62.
3. Nowack R, Andrassy J, Fischereder M, Unger M: Effects of dietary factors on drug transport and metabolism\and its impact on dosage guidelines in renal transplant patients. Clin Pharmacol Ther 2009;85:439-443.
4. Nowack R: Cytochrome P 450 enzyme-and transport-protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St. John's wort\and beyond! Nephrology 2008;13:337-347. (Pubitemid 351668338)
5. Stoves J, Newstead CG: Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study. Transplantation 2002;74:1794-1797. (Pubitemid 36019339)
6. He X, Johnston A: Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss? Transplant Proc 2004;36:1321-1326. (Pubitemid 38902968)
7. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J: Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum per-foratum). Transplantation 2000;69:2229-2230. (Pubitemid 30395071)
8. Nowack R, Nowak B: Herbal teas interfere with cyclosporin levels in renal transplant patients. Nephrol Dial Transplant 2005;20:2554-2556. (Pubitemid 41548889)
9. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al.: 6,7-Dihy-droxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-244. (Pubitemid 29142929)
10. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-1294. (Pubitemid 35284253)
11. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91. (Pubitemid 30609830)
12. Dirks NL, Huth B, Yates CR, Meibohm B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004;42:701-718. (Pubitemid 39625130)
13. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB: CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30:689-699.
14. Cattaneo D, Baldelli S, Perico N: Pharmacogenetics of immu-nosuppressants: progress, pitfalls and promises. Am J Transplant 2008;8:1374-1383. (Pubitemid 351989490)
15. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-282. (Pubitemid 30618491)